On November 22, 2024, Steven Binder, a Director at MannKind Corp (MNKD, Financial), sold 67,536 shares of the company. Following this transaction, the insider now owns 1,075,026 shares of MannKind Corp. The details of this transaction can be found in the SEC Filing.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's flagship product is an inhalable insulin therapy.
Over the past year, Steven Binder has sold a total of 172,536 shares and has not made any purchases. This activity is part of a broader trend within the company, where there have been 15 insider sells and no insider buys over the same period.
On the day of the recent sale, shares of MannKind Corp were trading at $6.89, giving the stock a market cap of $1.853 billion. The company's price-earnings ratio stands at 84.00, which is higher than the industry median of 26.81 and also higher than the company’s historical median price-earnings ratio.
The GF Value of MannKind Corp is estimated at $9.38, resulting in a price-to-GF-Value ratio of 0.73. This suggests that the stock is modestly undervalued based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also considers a GuruFocus adjustment factor based on the company’s past returns and growth, as well as future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
